Literature DB >> 34871162

The need for continuous quality assessment for providing optimal comprehensive care for patients with alpha-1 antitrypsin deficiency.

Anna Ptasinski1, Jacob Colello1, Joseph Ptasinski2, Gavin Barclay3, Timothy Craig4.   

Abstract

Background: Alpha-1-antitrypsin deficiency (AATD) is an orphan disease that mainly affecting the liver and the lung. This creates difficulties to ensure that comprehensive care is administered to both organ systems. Past assessments of care delivered to patients with AATD demonstrated that improvements are needed. For that reason, we reassessed a population of patients with AATD in a large health care system to see if past findings affected present care.
Methods: We performed electronic health record (EHR) reviews on all patients with documented AATD and confirmed the diagnosis by evidence of genotyping. We then selected the patients with the ZZ genotype to review comprehensive care. We further compared the findings in patients treated by different specialists (allergy immunology, gastroenterology, and pulmonary). The data were captured and assessed by using a secure web application for building and managing online surveys and data bases. REDCap.
Results: We found a total of 329 patients with diagnostic codes for AATD, of these, 203 patients had a confirmed abnormal genotype. Confirmed genotypes were MZ (n = 69), ZZ (n = 48), MS (n = 22), SZ (n = 22). Further focus was applied to the care of the ZZ population secondary to a predisposition to potential severe lung and liver disease. The findings suggest that care can be improved no matter which specialist cares for the patient.
Conclusion: Our study demonstrated that all three subspecialty groups had room for improvement in providing care to patients with AATD. Our study further demonstrated the need for recurrent quality-assurance programs that may be aided by care suggestions built into the EHR.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34871162      PMCID: PMC8654386          DOI: 10.2500/aap.2021.42.210067

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  16 in total

1.  A challenging diagnosis of alpha-1-antitrypsin deficiency: identification of a patient with a novel F/Null phenotype.

Authors:  Michael R Ringenbach; Erin Banta; Melissa R Snyder; Timothy J Craig; Faoud T Ishmael
Journal:  Allergy Asthma Clin Immunol       Date:  2011-11-13       Impact factor: 3.406

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

Review 3.  Alpha-1-Antitrypsin Deficiency Liver Disease.

Authors:  Dhiren Patel; Jeffrey H Teckman
Journal:  Clin Liver Dis       Date:  2018-08-22       Impact factor: 6.126

4.  Benefits Among Patients with Alpha-1 Antitrypsin Deficiency Enrolled in a Disease Management and Prevention Program.

Authors:  Jordan T Perkins; Radmila Choate; David M Mannino; Stephen R Browning; Robert A Sandhaus
Journal:  Chronic Obstr Pulm Dis       Date:  2016-12-24

5.  The Allergist's Role in Detection of Severe Alpha-1 Antitrypsin Deficiency.

Authors:  Theodore Kelbel; Darren Morris; Deirdre Walker; Maria Paula Henao; Timothy Craig
Journal:  J Allergy Clin Immunol Pract       Date:  2017-03-09

6.  Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey.

Authors:  J K Stoller; P Smith; P Yang; J Spray
Journal:  Cleve Clin J Med       Date:  1994 Nov-Dec       Impact factor: 2.321

Review 7.  Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder.

Authors:  Timothy J Craig; Maria Paula Henao
Journal:  Allergy       Date:  2018-07-26       Impact factor: 13.146

8.  Total and specific immunoglobulin E in induced sputum in allergic and non-allergic asthma.

Authors:  Astrid Crespo-Lessmann; Elena Curto; Eder Mateus; Lorena Soto; Alba García-Moral; Montserrat Torrejón; Alicia Belda; Jordi Giner; David Ramos-Barbón; Vicente Plaza
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

9.  Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Linda Nici; Manoj J Mammen; Edward Charbek; Paul E Alexander; David H Au; Cynthia M Boyd; Gerard J Criner; Gavin C Donaldson; Michael Dreher; Vincent S Fan; Andrea S Gershon; MeiLan K Han; Jerry A Krishnan; Fernando J Martinez; Paula M Meek; Michael Morgan; Michael I Polkey; Milo A Puhan; Mohsen Sadatsafavi; Don D Sin; George R Washko; Jadwiga A Wedzicha; Shawn D Aaron
Journal:  Am J Respir Crit Care Med       Date:  2020-05-01       Impact factor: 21.405

Review 10.  Needs for Systems Approaches to Better Treat Individuals With Severe Asthma: Predicting Phenotypes and Responses to Treatments.

Authors:  Luc Colas; Dorian Hassoun; Antoine Magnan
Journal:  Front Med (Lausanne)       Date:  2020-03-31
View more
  1 in total

1.  SARS-CoV-2 infection and the human immune system: A continuing journey of discovery.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2021-11-01       Impact factor: 2.587

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.